NO20083003L - Anvendelse av benzofuserte heterocykliske sulfamidderivater for a senke lipider og blodglykosenivaer - Google Patents

Anvendelse av benzofuserte heterocykliske sulfamidderivater for a senke lipider og blodglykosenivaer

Info

Publication number
NO20083003L
NO20083003L NO20083003A NO20083003A NO20083003L NO 20083003 L NO20083003 L NO 20083003L NO 20083003 A NO20083003 A NO 20083003A NO 20083003 A NO20083003 A NO 20083003A NO 20083003 L NO20083003 L NO 20083003L
Authority
NO
Norway
Prior art keywords
blood glucose
glucose levels
sulfamide derivatives
benzofused heterocyclic
lowering lipids
Prior art date
Application number
NO20083003A
Other languages
English (en)
Inventor
Allen B Reitz
Virginia L Smith-Swintosky
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20083003L publication Critical patent/NO20083003L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Foreliggende oppfinnelse er en fremgangsmåte for glukoserelaterte forstyrrelser og lipidrelaterte forstyrrelser som innbefatter administrering til et subjekt som trenger det av en terapeutisk effektiv mengde av ett eller flere nye benzosammensmeltede hererosyklussulfamidderivater med formel (I) eller formel (II) som definert heri. Foreliggende oppfinnelse angår videre fremgangsmåter for behandling som innbefatter samtidig behandling med et anti-diabetisk middel og anti-lipidmiddel og/eller en anti-fedmemiddel.
NO20083003A 2005-12-19 2008-07-03 Anvendelse av benzofuserte heterocykliske sulfamidderivater for a senke lipider og blodglykosenivaer NO20083003L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75167705P 2005-12-19 2005-12-19
US11/611,961 US8497298B2 (en) 2005-12-19 2006-12-18 Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
PCT/US2006/048477 WO2007092086A2 (en) 2005-12-19 2006-12-19 Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels

Publications (1)

Publication Number Publication Date
NO20083003L true NO20083003L (no) 2008-09-18

Family

ID=38225368

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083003A NO20083003L (no) 2005-12-19 2008-07-03 Anvendelse av benzofuserte heterocykliske sulfamidderivater for a senke lipider og blodglykosenivaer

Country Status (25)

Country Link
US (1) US8497298B2 (no)
EP (1) EP1973541B1 (no)
JP (1) JP5190374B2 (no)
KR (1) KR101363332B1 (no)
CN (1) CN101365441B (no)
AT (1) ATE486595T1 (no)
AU (1) AU2006337617B8 (no)
BR (1) BRPI0620011A2 (no)
CA (1) CA2634419C (no)
CR (1) CR10169A (no)
CY (1) CY1111161T1 (no)
DE (1) DE602006018066D1 (no)
DK (1) DK1973541T3 (no)
EA (2) EA016892B1 (no)
HK (1) HK1125287A1 (no)
HR (1) HRP20110008T1 (no)
IL (1) IL192101A (no)
MY (1) MY148866A (no)
NO (1) NO20083003L (no)
NZ (1) NZ569043A (no)
PL (1) PL1973541T3 (no)
PT (1) PT1973541E (no)
RS (1) RS51521B (no)
SI (1) SI1973541T1 (no)
WO (1) WO2007092086A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
CA2729056A1 (en) * 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2013049021A1 (en) 2011-09-29 2013-04-04 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
CA2850015A1 (en) 2011-09-29 2013-04-04 Janssen Pharmaceutica Nv Improved process for the preparation of sulfamide derivatives
WO2014034871A1 (ja) * 2012-08-30 2014-03-06 株式会社 三和化学研究所 脂質異常症の予防又は治療薬
CN105232544A (zh) * 2015-11-11 2016-01-13 朱忠良 一种抗糖尿病的口服药物组合物
CN105232543A (zh) * 2015-11-11 2016-01-13 朱忠良 一种抗糖尿病的口服药物组合物

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2527861A (en) * 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (no) * 1962-09-14
DE1211166B (de) 1962-11-20 1966-02-24 Ciba Geigy Verfahren zur Herstellung neuer Sulfamide
US3320314A (en) 1964-01-22 1967-05-16 Sandoz Ag Chlorobenzyl sulfamides
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3383414A (en) * 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
DE1542785A1 (de) 1965-07-24 1970-05-06 Bayer Ag Insekten- und milbenabweisende Mittel
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2022370A1 (de) 1970-05-08 1971-12-02 Bayer Ag N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) * 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
CA2054339C (en) 1990-11-02 2002-12-24 Francesco G. Salituro 3-amidoindolyl derivatives
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
DE69434652T2 (de) 1993-12-23 2007-03-01 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive pseudofructopyranose sulfamate
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
CA2216648A1 (en) * 1995-02-15 1996-08-22 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
JP3235448B2 (ja) * 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
AU7655796A (en) 1995-11-30 1997-06-19 C & C Research Laboratories Sulfamide derivatives
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
AP1285A (en) 1996-06-28 2004-06-24 Ortho Mcneil Pharm Inc Anticonvulsant sulfamate derivatives useful in treating obesity.
BR9711151A (pt) 1996-08-14 1999-08-17 Searle & Co Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
ES2241055T3 (es) 1996-08-23 2005-10-16 Endo Pharmaceuticals Inc Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico.
ATE226071T1 (de) 1996-10-08 2002-11-15 Ortho Mcneil Pharm Inc Antikonvulsive derivate zur behandlung von neuropathischem schmerz
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) * 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
DK72798A (da) 1998-05-28 1998-05-28 Novo Nordisk As Treatment of GABA-uptake related disorders
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
DK1143967T3 (da) 1999-01-19 2005-01-10 Ortho Mcneil Pharm Inc Anticonvulsive derivater egnede til behandling af Hortons hovedpine
AR022321A1 (es) 1999-01-21 2002-09-04 Ortho Mcneil Pharm Inc Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
ES2238999T3 (es) * 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
AU774732B2 (en) * 1999-04-08 2004-07-08 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
WO2000061140A1 (en) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
MXPA01010217A (es) * 1999-04-08 2005-09-08 Johnson & Johnson Derivados anticonvulsivos utiles en el tratamiento de trastornos neurodegenerativos cronicos.
CA2372806A1 (en) 1999-05-04 2000-11-09 Keith R. Edwards Intravenous valproate for acute treatment of migraine headache
DK1187603T3 (da) 1999-06-14 2007-12-17 Vivus Inc Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
AU782759B2 (en) * 1999-08-20 2005-08-25 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
FR2803848B1 (fr) 2000-01-19 2002-02-15 Adir Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6322503B1 (en) * 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
ATE320805T1 (de) * 2000-07-07 2006-04-15 Ortho Mcneil Pharm Inc Antikonvulsive derivate zur behandlung und vorbeugung der entwicklung von typ ii diabetes und syndrom x
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2002009694A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US6852738B2 (en) * 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
JP4732675B2 (ja) 2001-03-08 2011-07-27 ツェントルム フュール アンゲワンテ ナノテヒノロギー （ツェーアーエヌ） ゲーエムベーハー 常磁性ナノ粒子
CA2448160A1 (en) 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
EP1456022B1 (en) 2001-09-17 2009-11-11 Life Technologies Corporation Nanocrystals
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
RU2226357C1 (ru) 2003-02-12 2004-04-10 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева Способ диагностики эпилепсии у пациентов с доклинической стадией болезни
RU2246727C2 (ru) 2003-02-12 2005-02-20 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) Способ диагностики доклинической стадии эпилепсии
WO2004092116A1 (en) 2003-04-10 2004-10-28 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
AU2003223634A1 (en) 2003-04-16 2004-11-26 Siegfried B. Christensen Iv Peptide deformylase inhibitors
WO2004093912A1 (ja) 2003-04-23 2004-11-04 Kyowa Hakko Kogyo Co. Ltd. 好中球性炎症疾患の予防および／または治療剤
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
JP2007504228A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼組成物
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006010008A1 (en) 2004-06-22 2006-01-26 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
EP1781639B1 (en) 2004-07-28 2012-01-25 Janssen Pharmaceutica NV Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US20060276528A1 (en) 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
JP4912312B2 (ja) 2004-08-24 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体
AU2006239930A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070155823A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070191474A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191452A1 (en) 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
TW200738669A (en) 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US20070293476A1 (en) * 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
WO2009089210A1 (en) 2008-01-07 2009-07-16 Janssen Pharmaceutica N. V. Preparation of sulfamide derivatives
JP2011517448A (ja) 2008-03-26 2011-06-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾ−融合ダイオキシン誘導体の調製プロセス
US20090247618A1 (en) * 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
EA201071120A1 (ru) 2008-03-26 2011-06-30 Янссен Фармацевтика Н.В. Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
CA2729056A1 (en) * 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives

Also Published As

Publication number Publication date
ATE486595T1 (de) 2010-11-15
RS51521B (en) 2011-06-30
CA2634419A1 (en) 2007-08-16
CY1111161T1 (el) 2015-06-11
CN101365441A (zh) 2009-02-11
DE602006018066D1 (de) 2010-12-16
HRP20110008T1 (hr) 2011-02-28
CR10169A (es) 2009-01-14
JP2009520032A (ja) 2009-05-21
PT1973541E (pt) 2010-12-14
WO2007092086A2 (en) 2007-08-16
EA016892B1 (ru) 2012-08-30
CA2634419C (en) 2014-10-14
EA015606B1 (ru) 2011-10-31
DK1973541T3 (da) 2011-02-14
SI1973541T1 (sl) 2011-02-28
EP1973541A2 (en) 2008-10-01
BRPI0620011A2 (pt) 2011-10-25
PL1973541T3 (pl) 2011-04-29
NZ569043A (en) 2011-03-31
EA200870088A1 (ru) 2009-02-27
KR101363332B1 (ko) 2014-02-19
AU2006337617B8 (en) 2013-05-30
CN101365441B (zh) 2011-11-16
JP5190374B2 (ja) 2013-04-24
US8497298B2 (en) 2013-07-30
HK1125287A1 (en) 2009-08-07
MY148866A (en) 2013-06-14
EP1973541B1 (en) 2010-11-03
KR20080089408A (ko) 2008-10-06
IL192101A0 (en) 2009-08-03
US20070155821A1 (en) 2007-07-05
AU2006337617B2 (en) 2013-02-07
EA201000630A1 (ru) 2010-10-29
AU2006337617A1 (en) 2007-08-16
IL192101A (en) 2013-03-24
WO2007092086A3 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
NO20083003L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for a senke lipider og blodglykosenivaer
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
NO20083004L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av stoffmisbrukavhengighet
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
NO20084307L (no) Heterocykliske GPCR agonister
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
NO20080010L (no) GPCR-agonister
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
NO20072389L (no) Substituerte benzokinolizinderivater
NO20070893L (no) Hydantoinderivater for behandling av inflammasjonslidelser.
NO20070176L (no) Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20083026L (no) Terapeutisk middel for diabetes
ATE476422T1 (de) Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung
NO20065453L (no) Fenoksyalkykarboksylsyrederivater i behandlingen av inflammatoriske sykdommer.
NO20074084L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse
NO20055884L (no) Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
NO20070974L (no) Substituerte N-acyl-2-aminotiazoler
NO20054168L (no) Substituerte 3-(benzoylureido)-tiofenderivater, fremgangsmate for fremstilling og anvendelse derav
NO20054389L (no) Cyckloalkyl-substituerte alkansyrederivater, fremgangsmate for fremstilling og anvendelse derav som legemiddel
WO2003077949A3 (en) Methods of treating diabetes using pde 11a inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application